The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Mar. 03, 2022
Applicant:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Inventors:

Jean-Marie Cuillerot, Somerville, MA (US);

Mark Derose, Wilmington, MA (US);

Christopher Ryan Morgan, Southborough, MA (US);

Michael C. Naill, Stow, MA (US);

Avni Shah, Framingham, MA (US);

Assignee:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/138 (2006.01); A61K 31/167 (2006.01); A61K 31/573 (2006.01); A61K 39/00 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39591 (2013.01); A61K 31/138 (2013.01); A61K 31/167 (2013.01); A61K 31/573 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/283 (2013.01); C07K 16/2851 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01);
Abstract

This disclosure relates to methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen such as HER2. Provided are uses of the multi-specific binding protein in combination with a corticosteroid to reduce the risk of infusion-related reactions. Also provided are uses of the multi-specific binding protein in treating cancer that has low or moderate HER2 expression level. The present disclosure also relates to pharmaceutical formulations comprising the multi-specific binding proteins.


Find Patent Forward Citations

Loading…